Clinical Trials Sponsored by Abgenix

Total 157 results

argenx

Not yet recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Myasthenia Gravis
argenx

Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (ADAPT SERON)

Generalized Myasthenia Gravis

United States
argenx

Recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

Korea, Republic of, Thailand, United States, Bulgaria, Taiwan, Argentina, Belgium, Cyprus, Denmark, France, Georgia, Germany, Greece, Italy, Lithuania, Czechia, Sweden
argenx

Recruiting

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (VARVARA)

Delayed Graft Function

Australia, Spain, Belgium, France, Portugal, Canada
argenx

Recruiting

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD+)

Bullous Pemphigoid

Netherlands, Spain, Germany, United Kingdom, China, Italy, Hungary, United States, Croatia, Japan, Serbia, Bulgaria, Israel, Australia, Greece, Slovakia
argenx

Recruiting

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA+)

Multifocal Motor Neuropathy (MMN)

United Kingdom, Spain, United States, Italy, Netherlands, Germany, France, Belgium, Canada, Poland, Austria
argenx

Recruiting

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis (ADAPT Jr +)

Generalized Myasthenia Gravis

United States, Netherlands, Belgium, Poland, United Kingdom
argenx

Active, not recruiting

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

Generalized Myasthenia Gravis

Georgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
argenx

Active, not recruiting

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA)

Multifocal Motor Neuropathy

United States, France, Germany, Belgium, Italy, Netherlands, Canada, United Kingdom, Austria, Poland, Spain
argenx

Active, not recruiting

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)

Bullous Pemphigoid

United States, Australia, Bulgaria, China, Croatia, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
argenx

Completed

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Healthy Volunteers

Netherlands
argenx

Completed

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Pemphigus Vulgaris | Pemphigus Foliaceus

Germany, Hungary, Israel, Italy, Ukraine
argenx

Withdrawn

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) (ADVANCE2)

Primary Immune Thrombocytopenia (ITP)
argenx

Completed

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Healthy Volunteers

Netherlands
argenx

Completed

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Cancer

Belgium
argenx

Completed

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Cancer

Belgium
Apogenix AG

Completed

Asunercept in Patients With Severe COVID-19 (ASUNCTIS)

Covid19 | COVID-19 Induced Pneumonia

Spain, Russian Federation
TiGenix n.v.

Completed

RCT of ChondroCelect® (in an ACI Procedure) vs Microfracture in the Repair of Cartilage Defects of the Knee (TIGACT01)

Articular Cartilage Lesion of the Femoral Condyle

Belgium, Croatia, Germany, Netherlands
Algenis SpA

Completed

Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study

Back Pain | Acute Pain

Chile
TiGenix n.v.

Terminated

A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects (OMCM)

Osteochondral Defects

United Kingdom, Germany, Hungary, Belgium
Zogenix MDS, Inc.
Zogenix, Inc.

Withdrawn

A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)

Thymidine Kinase 2 Deficiency
Zogenix MDS, Inc.
Zogenix, Inc.

Completed

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

Thymidine Kinase 2 Deficiency

Spain, United States, Russian Federation, Turkey
Zogenix, Inc.
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Active, not recruiting

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Dravet Syndrome | Epileptic Encephalopathy | Lennox Gastaut Syndrome

United States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Mexico, Netherlands, Poland, Spain, Sweden, United Kingdom
Zogenix, Inc.
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.

Terminated

European Non-interventional Study on Refractory Epilepsy With Developmental Delay

Refractory Epilepsy | Development Delay

Germany, Spain, France, Italy
Tissue Regenix Ltd

Recruiting

OrthoPureXT Multiligament PMCF Study

Multiligament Knee Injuries

United Kingdom
Tigenix S.A.U.

Completed

Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.

Crohn's Disease | Anal Fistula

Spain
Tigenix S.A.U.

Completed

Intralymphatic eASC Administration in Healthy Volunteers

Localized Adverse Reaction to Administration of Drug

Spain
Algenis SpA
Covance

Completed

NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects

Safety
Tigenix S.A.U.

Completed

Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers (CELLULA)

Sepsis

Netherlands
Tissue Regenix Ltd

Completed

dCell Vascular Patch in Peripheral Vascular Surgery Study for CE Mark Submission

Peripheral Arterial Vascular Occlusion

Hungary, Netherlands
Yale University
Agennix

Completed

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Advanced Cancers

United States
Algenis SpA
Oncoclínicas

Recruiting

Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy

Chemotherapy-induced Peripheral Neuropathy

Brazil
Tigenix S.A.U.

Completed

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) (ADMIRE-CD-II)

Crohn's Disease

United States, Spain, United Kingdom, Italy, Germany, Canada, Belgium, Denmark, Poland, Czechia, France, Hungary, Israel, Puerto Rico, Sweden
Tissue Regenix Ltd

Completed

Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament

Knee Injuries

Poland, Spain, United Kingdom
Tigenix S.A.U.

Completed

Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa (TCEB)

EPIDERMOLYSIS BULLOSA

Spain
Tigenix S.A.U.

Completed

Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial (LTE)

Complex Perianal Fistula

Spain
Tigenix S.A.U.

Completed

Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients

Rheumatoid Arthritis Aggravated

Spain
Tigenix S.A.U.

Completed

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE-CD)

Crohn's Disease

Spain, Belgium, Netherlands, France, Israel, Italy, Austria, Germany
Tigenix S.A.U.

Completed

Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease (FATT1)

Anal Fistula

Spain, Germany, United Kingdom
Tigenix S.A.U.

Terminated

Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease (FATT)

Crohn Disease | Complex Perianal Fistula

Spain, Netherlands, Austria
Tissue Regenix Ltd

Suspended

Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus

Knee Injuries

Poland, United Kingdom
Vitaccess Ltd
argenx

Recruiting

The Impact of Myasthenia Gravis in the Real World

Myasthenia Gravis

United Kingdom
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Primary Immune Thrombocytopenia

Austria, Belgium, France, Germany, Spain, Czechia, Hungary, Poland, Ukraine, United Kingdom
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Myasthenia Gravis

Italy, United States, Belgium, Canada, Netherlands, Poland, Spain, Sweden
Zogenix, Inc.

Completed

A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)

Healthy
Zogenix, Inc.

Completed

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Chronic Pain

United States
IgGenix Australia Pty Ltd

Not yet recruiting

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Peanut Allergy
Zogenix, Inc.

Approved for marketing

ZX008 Expanded Access Protocol

Dravet Syndrome
Zogenix, Inc.

Completed

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

Back Pain Lower Back Chronic

United States

3

Subscribe